Drug intelligence / Profile preview

GKIND010A

Development stage: Preclinical
Lead developer: China Resources Guokang
Modality: Small Molecules
Administration: Oral

Overview

GKIND010A is a small molecule modulator of the sphingosine-1-phosphate (S1P) receptor currently under development by China Resources Guokang Pharmaceutical. It is designed to treat inflammatory bowel disease (IBD), specifically ulcerative colitis, by modulating S1P receptor signaling. This mechanism typically regulates immune-cell trafficking, preventing the egress of lymphocytes from lymph nodes into the circulation and subsequent infiltration into inflamed tissues. As of 2024, the program is in the IND-enabling (Pre-IND) stage.

Targets

EDG1 (Sphingosine-1-phosphate receptors)

Beyond the preview

Go deeper on GKIND010A.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GKIND010A.

Explore the full profile